Status:
UNKNOWN
The Effect of Topical Treatment With Combigan Compared to Timolol and Brimonidine on Pupil Diameter
Lead Sponsor:
Carmel Medical Center
Conditions:
Healthy
Eligibility:
All Genders
18-30 years
Phase:
PHASE2
Brief Summary
In this study we will explore the combined effect of Brimonidine and Timolol 0.5% (Combigan) eye drops on pupil dilation. It is a well studied phenoma that Brimonidine and a miotic effect on the pupil...
Detailed Description
In this study we will explore the combined effect of Brimonidine and Timolol 0.5% (Combigan) eye drops on pupil dilation. It is a well studied phenoma that Brimonidine and a miotic effect on the pupil...
Eligibility Criteria
Inclusion
- Healthy adults subjects with no ocular pathology
- Non pregnant women
- Normal pupil response
Exclusion
- Chronic topical treatment
- Systemic medication affecting autonomic nerve system
- History of intra-ocular surgery
- Irregular pupil
- History of ocular neurological or severe cardio-vascular disease
Key Trial Info
Start Date :
October 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2016
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT02214680
Start Date
October 1 2015
End Date
December 1 2016
Last Update
October 14 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Carmel Medical Center
Haifa, Israel, 34362